# US 2021/0171440 A1 · 1,4-disubstituted imidazole derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171440 A1
- Document ID: US20210171440A1
- Status: Published application
- Kind: A1
- Application number: 17/073,175
- Filed: 2020-10-16
- Published: 2021-06-10
- Earliest claimed: 2015-06-22
- Assignees: Sumitomo Dainippon Pharma Co., Ltd.
- Applicants: Sumitomo Dainippon Pharma Co., Ltd.
- Inventors: Hitoshi Ban; Manabu Kusagi; Shingo Tojo; Futoshi Hasegawa; Miki Hashizume
- Web page: https://patentgrep.com/patent/US20210171440A1

## CPC

- C07C 233/88: having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
- A61P 35/02: specific for leukemia
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1′) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.

## Claims

### Claim at position 1

1-41. (canceled)

### Claim 42

A process of preparing a compound of formula (1-7):
or a pharmaceutically acceptable salt thereof, wherein ring Q1 is optionally-substituted C6-10 aryl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered heteroaryl;
R1 and R2 are each independently hydrogen, halogen, or C1-6 alkyl, wherein said C1-6 alkyl is optionally substituted with 1 to 3 halogen atoms;
W1 is optionally-substituted C1-4 alkylene;
ring Q2 is 5- to 10-membered heteroaryl;
W3 is optionally-substituted C1-4 alkylene, optionally-substituted C3-4 alkenylene, or optionally-substituted C3-4 alkynylene;
n is 1, 2, 3, 4, or 5;
each R4 is independently hydrogen, halogen, optionally-substituted C1-6 alkyl, optionally-substituted C1-6 alkoxy, optionally-substituted C3-10 cycloalkyl, optionally-substituted C2-6 alkenyl, optionally-substituted C2-6 alkynyl, cyano, or optionally-substituted amino;
or, any R4 and W3 attached to adjacent carbon atoms on ring Q2, together with the carbon atoms to which they are attached, form a 3- to 8-membered cycloalkane ring; and
R5 is
(1) hydroxy,
(2) C1-6 alkoxy optionally substituted with 1 to 3 substituents each independently halogen, hydroxy, C1-6 alkoxy, or C6-10 aryl, wherein said C1-6 aryl is optionally substituted with 1 to 4 substituents each independently halogen, C1-6 alkyl, or C1-6 alkoxy,
(3) amino, which is optionally substituted with 1 or 2 C1-6 alkyl, or
(4) C1-6 alkyl-carbonylamino, wherein the alkyl moiety thereof is optionally substituted with 1 to 3 halogen;
the process comprising:
reacting compound (1-6):
with compound (1-2):
in an inert solvent in the presence of a condensation agent.

### Claim 43 (depends on 42)

The process according to claim 42, wherein the compound (1-2) is prepared according to a process comprising hydrolyzing compound (1-1):
wherein R101 is C1-6 alkyl.

### Claim 44 (depends on 42)

The process according to claim 42, wherein the compound (1-6) is prepared according to a process comprising reacting compound (1-3):
with compound (1-4):
wherein L is a leaving group, to give compound (1-5):
and reducing the nitro group of compound (1-5) to give compound (1-6).

### Claim 45 (depends on 43)

The process according to claim 43, wherein the compound (1-1) is compound (2-5), (2-8), (2-11), (2-13) or (13-2):
wherein R102 is optionally-substituted C1-6 alkyl, R103 is optionally-substituted phenyl, and Ra and Rb are each independently hydrogen or methyl.

### Claim 46 (depends on 43)

The process according to claim 43, wherein the compound (1-1) is compound (4-3):

### Claim 47 (depends on 43)

The process according to claim 43, wherein the compound (1-1) is compound (5-1):

### Claim 48 (depends on 43)

The process according to claim 43, wherein the compound (1-1) is compound (6-2):

### Claim 49 (depends on 43)

The process according to claim 43, wherein the compound (1-1) is compound (7-2):

### Claim 50

A process of preparing a compound of formula (11-4):
or a pharmaceutically acceptable salt thereof, wherein ring Q1 is optionally-substituted C6-10 aryl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered heteroaryl;
R1 and R2 are independently hydrogen, halogen, or C1-6 alkyl, wherein said C1-6 alkyl is optionally substituted with 1 to 3 halogen atoms;
W1 is optionally-substituted C1-4 alkylene;
ring Q2 is 5- to 10-membered heteroaryl;
W3 is optionally-substituted C1-4 alkylene, optionally-substituted C3-4 alkenylene, or optionally-substituted C3-4 alkynylene;
n is 1, 2, 3, 4, or 5;
each R4 is independently hydrogen, halogen, optionally-substituted C1-6 alkyl, optionally-substituted C1-6 alkoxy, optionally-substituted C3-10 cycloalkyl, optionally-substituted C2-6 alkenyl, optionally-substituted C2-6 alkynyl, cyano, or optionally-substituted amino;
or, any R4 and W3 attached to adjacent carbon atoms on ring Q2, together with the carbon atoms to which they are attached, form a 5- to 8-membered cycloalkane ring; and
R5 is
(1) hydroxy,
(2) C1-6 alkoxy, which is optionally substituted with 1 to 3 substituents each independently halogen, hydroxy, C1-6 alkoxy, or C6-10 aryl, wherein said C6-10 aryl is optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, C1-6 alkyl, or C1-6 alkoxy,
(3) amino, which is optionally substituted with 1 or 2 C1-6 alkyl, or
(4) C1-6 alkyl-carbonylamino, wherein the alkyl moiety thereof is optionally substituted with 1 to 3 halogen;
the process comprising:
hydrolyzing compound (11-1):
wherein R101 is C1-6 alkyl group, to give compound (11-2):
and reacting the compound (11-2) with compound (11-3):
in an inert solvent in the presence of a condensation agent.

### Claim 51

A process of preparing a compound of formula (12-5):
or a pharmaceutically acceptable salt thereof, wherein ring Q1 is optionally-substituted C6-10 aryl, optionally-substituted C3-10 cycloalkyl, or optionally-substituted 5- to 10-membered heteroaryl;
R1 and R2 are independently hydrogen, halogen, or C1-6 alkyl wherein said C1-6 alkyl is optionally substituted with 1 to 3 halogen atoms;
W1 is optionally-substituted C1-4 alkylene;
ring Q2 is 5- to 10-membered heteroaryl;
n is 1, 2, 3, 4, or 5;
each R4 is independently hydrogen, halogen, optionally-substituted C1-6 alkyl, optionally-substituted C1-6 alkoxy, optionally-substituted C3-10 cycloalkyl, optionally-substituted C2-6 alkenyl, optionally-substituted C2-6 alkynyl, cyano, or optionally-substituted amino;
or, any R4 and W3 attached to adjacent carbon atoms on ring Q2, together with the carbon atoms to which they are attached, form a 3- to 8-membered cycloalkane ring; and
Rc and Rd are independently hydrogen, deuterium, or methyl;
the process comprising:
reacting compound (12-1):
wherein R101 is C1-6 alkyl, with a haloacetate in an inert solvent in the presence of a base to give compound (12-2):
cleaving the tert-butytester group in the compound (12-2) under an acid condition to give compound (12-3):
reacting compound (1-6):
with the compound (12-3) to give compound (12-4):
in an inert solvent in the presence of a condensation agent; and
reacting the compound (12-4) with an organometallic reagent or a hydride reducing agent in an inert solvent.

### Claim 52 (depends on 42)

A method of treating a cancer, administering a therapeutically effective amount of the compound of formula (1-7), or a pharmaceutically acceptable salt thereof, to a patient in need thereof, the compound of formula (1-7) is prepared by the process according to claim 42.

### Claim 53 (depends on 42)

A method of treating a cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (1-7), or a pharmaceutically acceptable salt thereof, in combination with an additional anti-cancer agent selected from the group consisting of an anti-cancerous alkylating agent, an anti-cancerous antimetabolite, an anti-cancerous antibiotic, a plant-based anti-cancer agent, an anti-cancerous platinum coordination compound, an anti-cancerous camptothecin derivative, an anti-cancerous tyrosine kinase inhibitor, a serine-threonine kinase, a phospholipid kinase, a monoclonal antibody, an interferon, a biological response modifier, a hormone preparation, an immune checkpoint inhibitor, an epigenetics-related molecule inhibitor, a post-translational protein modification inhibitor, and other anti-cancer agent or pharmaceutically acceptable salt thereof; and
wherein the compound of formula (1-7), or a pharmaceutically acceptable salt thereof, is prepared by the process according to claim 42.
